<HashMap><database>NODE</database><scores/><additional><omics_type>Transcriptomics</omics_type><submitter>Jiexian Ma</submitter><technology_type>RNA-Seq</technology_type><experiment_platform>Illumina HiSeq 2000</experiment_platform><full_dataset_link>https://www.biosino.org/node/experiment/detail/OEX00014403</full_dataset_link><experiment_library_selection>RANDOM</experiment_library_selection><experiment_library_layout>Paired</experiment_library_layout><sample_count>1</sample_count><tissue>['blood Cell Line']</tissue><taxonomy>['Homo sapiens']</taxonomy><repository>NODE</repository></additional><is_claimable>false</is_claimable><name>OEX_Jiexian_2108201709</name><description>To begin to elucidate the mechanism of action of decitabine with etoposide-based(D+E) treatment, we selected the TP53 mutation (THP-1 and U937) and TP53 WT (MOLM13) AML/MDS cell lines and treated them with etoposide or aclarubicin according to the indicated dose</description><dates><publication>2021-08-21</publication><submission>2021-08-20</submission></dates><accession>OEX00014403</accession><cross_references><NODE>OEP00002612</NODE></cross_references></HashMap>